12/08/2021 | Press release | Distributed by Public on 12/08/2021 07:03
We are pleased to invite investors and analysts to participate in our virtual event on Wednesday,
15 December, 2021, highlighting Roche data presented at the virtual American Society of Hematology (ASH) 63rd Annual Meeting, from 11-14th December.
16:00 - 17:30 CET / 15:00 - 16:30GMT
10:00 - 11:30 am EST / 7:00 - 8:30 am PST
The webinar will start with a presentation, followed by a Q&A session (live access to the speakers).
Agenda:
Welcome
Karl Mahler, Head of Investor Relations
Hematology franchise overview
Peter Ahnesorg, Franchise Head Hematology
Review of key clinical data presented at ASH: Hemlibra, mosun,glofit,cevostamab
Charles Fuchs, Senior Vice President - Global Head Of Oncology And Hematology Product Development
Presentation of POLARIX data
Franck Morschhauser, MD, PhD, Professor of Hematology, University of Lille; President of LYSA, LYSARC
Q&A
The slides will be available for download at 15:00 CET on the day of the event. > click here
Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.
Should you be unable to register for the webinar due to your company IT policy, please send an email to [email protected].
A replay of the event will be available via > ir.roche.com
Best regards, | |
Karl Mahler Head of Investor Relations |
Loren Kalm Head of Investor Relations, North America |
Roche Investor Relations | |
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: [email protected] |
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: [email protected] |
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: [email protected] |
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: [email protected] |
Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: [email protected] |
|
Investor Relations North America | |
Loren Kalm Phone: +1 650 225 3217 e-mail: [email protected] |